Preconditioning: A paradigm shift in the biology of myocardial ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 1, 2007, Pages

  Bolli, Roberto ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cyclooxygenase 2; Nitric oxide synthase; Protection

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; BRADYKININ B2 RECEPTOR; CELECOXIB; ENDOTHELIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MUSCARINIC M2 RECEPTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; OPIATE; PROSTACYCLIN; SUPEROXIDE DISMUTASE;

DRUG MECHANISM; GENE THERAPY; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CYCLOOXYGENASE 2; HEART; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN SPECIES;

EID: 33846244291     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00712.2006     Document Type: Review

References (39)

1. Abete P, Ferrara N, Cioppa A, Ferrara P, Bianco S, Calabrese C, Cacciatore F, Longobardi G, Rengo F. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 27: 1777-1786, 1996.
2. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 302: 723-727, 1994.
3. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918, 2001.
4. Bolli R. The late phase of preconditioning. Circ Res 87: 972-983, 2000.
5. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, and Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95: 125-134, 2004.
6. Bolli R, Dawn B, Tang XL, Qiu Y, Ping P, Xuan YT, Jones WK, Takano H, Guo Y, Zhang J. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 93: 325-338, 1998.
7. Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y, Zhang Q, Jadoon AK. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 81: 1094-1107, 1997.
8. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519, 2002.
9. Dawn B, Xuan YT, Marian M, Flaherty MP, Murphree SS, Smith TL, Bolli R, Jones WK. Cardiac-specific abrogation of NF-κB activation in mice by transdominant expression of a mutant IκBα. J Mol Cell Cardiol 33: 161-173, 2001.
10. del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res 55: 642-659, 2002.
11. Fenton RA, Dickson EW, Meyer TE, Dobson JG Jr. Aging reduces the cardioprotective effect of ischemic preconditioning in the rat heart. J Mol Cell Cardiol 32: 1371-1375, 2000.
12. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96: 11507-11512, 1999.
13. Guo Y, Luo C, Dawn B, Tan W, Wu WJ, Hunt G, Zhu X, Li Q. The cardioprotection afforded by iNOS gene therapy is mediated by COX-2 via an NF-κB-dependent pathway (Abstract). Circulation 110: III-29, 2004.
14. Guo Y, Wu WJ, Zhu XP, Li Q, Tang XL, Bolli R. Exercise-induced late preconditioning is triggered by generation of nitric oxide (Abstract). J Mol Cell Cardiol 33: A41, 2001.
15. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40: 16-23, 2006.
16. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310: 1966-1970, 2005.
17. Kremastinos DT, Bofilis E, Karavolias GK, Papalois A, Kaklamanis L, Iliodromitis EK. Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis 150: 81-89, 2000.
18. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47: 1716-1721, 2004.
19. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72: 1293-1299, 1993.
20. Li Q, Guo Y, Luo C, Tan W, Wu WJ, Xu B, Siddiqui T, Rokosh GD, Bolli R. Long-term protection against myocardial infarction with cyclooxygenase-2 (COX-2) gene therapy via a recombinant adeno-associated viral (rAAV) vector (Abstract). Circulation 110: III-107, 2004.
21. Li Q, Guo Y, Tan W, Stein AB, Dawn B, Wu WJ, Zhu X, Lu X, Xu X, Siddiqui T, Tiwari S, Bolli R. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 290: H584-H589, 2006.
22. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, Wu WJ, Zhu Y, Bolli R. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92: 741-748, 2003.
23. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264-1272, 1993.
24. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
25. Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 38: 1741-1747, 2001.
26. Shinmura K, Bolli R. The risk for myocardial infarction with cyclooxygenase-2 inhibitors. Ann Intern Med 143: 615-618, 2005.
27. Shinmura K, Nagai M, Tamaki K, Bolli R. Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol 99: 46-55, 2004.
28. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202, 2000.
29. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, Bolli R. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602-608, 2002.
30. Tang XL, Stein AB, Shirk G, Bolli R. Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits. Basic Res Cardiol 99: 395-403, 2004.
31. Tang XL, Takano H, Xuan YT, Sato H, Kodani E, Dawn B, Zhu Y, Shirk G, Wu WJ, Bolli R. Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. Circulation 112: 2149-2156, 2005.
32. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54: 2360-2364, 2005.
33. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T, Takeda H, Hori M. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 34: 2120-2125, 1999.
34. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 74: 711-738, 2005.
35. Wang Y, Guo Y, Zhang SX, Wu WJ, Wang J, Bao W, Bolli R. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 34: 5-15, 2002.
36. Wu WJ, Xuan YT, Tan W, Zhu X, Zhu Y, Guo Y. The loss of ischemic preconditioning in the senescent heart is associated with impaired upregulation of inducible nitric oxide synthase and cyclooxygenase-2 (Abstract). Circulation 108: IV-187, 2003.
37. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, Bolli R. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 35: 525-537, 2003.
38. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, Bolli R. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84: 1095-1109, 1999.
39. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151, 2003.